PDT Partners LLC bought a new position in shares of Enfusion, Inc. (NYSE:ENFN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 91,315 shares of the company's stock, valued at approximately $867,000. PDT Partners LLC owned approximately 0.07% of Enfusion at the end of the most recent quarter.
Several other large investors also recently modified their holdings of the business. RiverPark Advisors LLC acquired a new position in Enfusion during the 2nd quarter worth approximately $68,000. Arizona State Retirement System bought a new stake in shares of Enfusion in the 2nd quarter valued at about $86,000. Price T Rowe Associates Inc. MD acquired a new stake in Enfusion in the 1st quarter valued at about $102,000. Harbor Capital Advisors Inc. grew its holdings in Enfusion by 12.4% during the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company's stock worth $113,000 after purchasing an additional 1,315 shares during the period. Finally, Belvedere Trading LLC acquired a new position in Enfusion during the third quarter worth approximately $114,000. 81.05% of the stock is currently owned by institutional investors.
Enfusion Price Performance
ENFN stock remained flat at $10.14 during midday trading on Tuesday. 348,311 shares of the company's stock were exchanged, compared to its average volume of 383,278. Enfusion, Inc. has a 1 year low of $7.52 and a 1 year high of $10.40. The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of 253.56, a price-to-earnings-growth ratio of 3.79 and a beta of 0.97. The stock's 50 day simple moving average is $9.34 and its 200-day simple moving average is $8.90.
Enfusion Profile
(
Free Report)
Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.
Featured Articles
Before you consider Enfusion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enfusion wasn't on the list.
While Enfusion currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.